Concepedia

Publication | Closed Access

ADVERSE EVENTS AFTER INTRAVITREAL INFLIXIMAB (REMICADE)

130

Citations

18

References

2010

Year

Abstract

Low-dose intravitreal infliximab was not well tolerated in this small group of patients and was both immunogenic and probably retinotoxic.

References

YearCitations

Page 1